Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
230
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy

Chengyuan Gua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Suzhou, China;c Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
,
Qian Wua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Suzhou, China;c Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
,
Jingren Zhanga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Suzhou, China;c Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
,
Liqing Kangd School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China;e Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, ChinaView further author information
,
Lei Yud School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China;e Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, ChinaView further author information
,
Huiying Qiua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Suzhou, China;c Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
,
Depei Wua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Suzhou, China;c Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
,
Suning Chena National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Suzhou, China;c Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaView further author information
&
Xiaofei Yanga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Suzhou, China;c Collaborative Innovation Center of Hematology, Soochow University, Suzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 495-498 | Received 03 May 2022, Accepted 11 Nov 2022, Published online: 17 Nov 2022

References

  • Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2019;25(4):e123–e127.
  • Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195.
  • Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45–55.
  • Acharya UH, Dhawale T, Yun S, et al. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 2019;12(3):195–205.
  • Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.
  • Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56.
  • Yang X, Dai H, Kang L, et al. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Hematol Oncol. 2019;37(5):655–658.
  • Curran SA, Shyer JA, St Angelo ET, et al. Human dendritic cells mitigate NK-Cell dysfunction mediated by nonselective JAK1/2 blockade. Cancer Immunol Res. 2017;5(1):52–60.
  • Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.
  • Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832–3842.
  • Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1(19):1533–1536.
  • Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813–822.
  • Haile WB, Gavegnano C, Tao S, et al. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model. Neurobiol Dis. 2016;92(Pt B):137–143.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.